|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
dopamine reuptake inhibitor
|
|
gptkbp:affects
|
norepinephrine levels
dopamine levels
|
|
gptkbp:appointed_by
|
gptkb:skincare_product
oral tablet
extended-release tablet
|
|
gptkbp:approves
|
gptkb:1955
|
|
gptkbp:brand
|
gptkb:Aptensio_XR
gptkb:Concerta_ODT
gptkb:Daytrana_patch
gptkb:Focalin
gptkb:Focalin_XR
gptkb:Metadate_CD
gptkb:Methylin
gptkb:Quillivant_XR
gptkb:Ritalin_LA
|
|
gptkbp:contraindication
|
gptkb:sneaker
heart problems
hyperthyroidism
|
|
gptkbp:formulation
|
gptkb:beer
gptkb:spacecraft
gptkb:tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Methylphenidate
|
|
gptkbp:ingredients
|
C14 H19 N O2
|
|
gptkbp:interacts_with
|
antidepressants
MAO inhibitors
antihypertensives
|
|
gptkbp:is_used_for
|
gptkb:Attention_Deficit_Hyperactivity_Disorder_(ADHD)
Narcolepsy
|
|
gptkbp:legal_issue
|
controlled substance
|
|
gptkbp:marketed_as
|
gptkb:Daytrana
gptkb:Concerta
gptkb:Ritalin
Metadate
|
|
gptkbp:related_to
|
gptkb:amphetamine
cocaine
|
|
gptkbp:side_effect
|
anxiety
headache
nausea
decreased appetite
insomnia
|
|
gptkbp:symptoms
|
gptkb:historical_event
fatigue
sleep disturbances
|
|
gptkbp:type_of
|
113-45-1
|
|
gptkbp:bfsParent
|
gptkb:Methylin
|
|
gptkbp:bfsLayer
|
4
|